Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.

Cucè M, Gallo Cantafio ME, Siciliano MA, Riillo C, Caracciolo D, Scionti F, Staropoli N, Zuccalà V, Maltese L, Di Vito A, Grillone K, Barbieri V, Arbitrio M, Di Martino MT, Rossi M, Amodio N, Tagliaferri P, Tassone P, Botta C.

J Hematol Oncol. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9.

2.

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.

Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D, Cannataro M, Arpino G, Santini D, Tassone P, Tagliaferri P.

Clin Pharmacol Ther. 2019 Feb 10. doi: 10.1002/cpt.1391. [Epub ahead of print]

PMID:
30739312
3.

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives.

Arbitrio M, Martino MTD, Scionti F, Barbieri V, Pensabene L, Tagliaferri P.

High Throughput. 2018 Dec 18;7(4). pii: E40. doi: 10.3390/ht7040040. Review.

4.

From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology.

Gallo Cantafio ME, Grillone K, Caracciolo D, Scionti F, Arbitrio M, Barbieri V, Pensabene L, Guzzi PH, Di Martino MT.

High Throughput. 2018 Oct 26;7(4). pii: E33. doi: 10.3390/ht7040033. Review.

5.

The Cytoscan HD Array in the Diagnosis of Neurodevelopmental Disorders.

Scionti F, Di Martino MT, Pensabene L, Bruni V, Concolino D.

High Throughput. 2018 Sep 14;7(3). pii: E28. doi: 10.3390/ht7030028. Review.

6.

The potential role of miRNAs in multiple myeloma therapy.

Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, Tassone P.

Expert Rev Hematol. 2018 Oct;11(10):793-803. doi: 10.1080/17474086.2018.1517041. Epub 2018 Sep 12. Review.

PMID:
30148649
7.

miR-22 suppresses DNA ligase III addiction in multiple myeloma.

Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M, Botta C, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, Tassone P.

Leukemia. 2019 Feb;33(2):487-498. doi: 10.1038/s41375-018-0238-2. Epub 2018 Aug 17.

8.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P.

Blood. 2018 Sep 6;132(10):1050-1063. doi: 10.1182/blood-2018-03-836601. Epub 2018 Jul 11.

9.

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.

Scionti F, Di Martino MT, Sestito S, Nicoletti A, Falvo F, Roppa K, Arbitrio M, Guzzi PH, Agapito G, Pisani A, Riccio E, Concolino D, Pensabene L.

Oncotarget. 2017 Nov 18;8(64):107558-107564. doi: 10.18632/oncotarget.22505. eCollection 2017 Dec 8.

10.

Genetic variants associated with gastrointestinal symptoms in Fabry disease.

Di Martino MT, Scionti F, Sestito S, Nicoletti A, Arbitrio M, Hiram Guzzi P, Talarico V, Altomare F, Sanseviero MT, Agapito G, Pisani A, Riccio E, Borrelli O, Concolino D, Pensabene L.

Oncotarget. 2016 Dec 27;7(52):85895-85904. doi: 10.18632/oncotarget.13135.

11.

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.

Arbitrio M, Di Martino MT, Scionti F, Agapito G, Guzzi PH, Cannataro M, Tassone P, Tagliaferri P.

Oncotarget. 2016 Aug 16;7(33):54028-54050. doi: 10.18632/oncotarget.9927. Review.

12.

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.

Arbitrio M, Di Martino MT, Barbieri V, Agapito G, Guzzi PH, Botta C, Iuliano E, Scionti F, Altomare E, Codispoti S, Conforti S, Cannataro M, Tassone P, Tagliaferri P.

Cancer Chemother Pharmacol. 2016 Jan;77(1):205-9. doi: 10.1007/s00280-015-2916-3. Epub 2015 Nov 25.

PMID:
26607259
13.

Advances in Alport syndrome diagnosis using next-generation sequencing.

Artuso R, Fallerini C, Dosa L, Scionti F, Clementi M, Garosi G, Massella L, Epistolato MC, Mancini R, Mari F, Longo I, Ariani F, Renieri A, Bruttini M.

Eur J Hum Genet. 2012 Jan;20(1):50-7. doi: 10.1038/ejhg.2011.164. Epub 2011 Sep 7.

14.

High frequency of COH1 intragenic deletions and duplications detected by MLPA in patients with Cohen syndrome.

Parri V, Katzaki E, Uliana V, Scionti F, Tita R, Artuso R, Longo I, Boschloo R, Vijzelaar R, Selicorni A, Brancati F, Dallapiccola B, Zelante L, Hamel CP, Sarda P, Lalani SR, Grasso R, Buoni S, Hayek J, Servais L, de Vries BB, Georgoudi N, Nakou S, Petersen MB, Mari F, Renieri A, Ariani F.

Eur J Hum Genet. 2010 Oct;18(10):1133-40. doi: 10.1038/ejhg.2010.59. Epub 2010 May 12.

Supplemental Content

Loading ...
Support Center